SARS-CoV Spike Protein Synthetic Peptides
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccines and antiviral drugs are inadequate to effectively prevent and treat SARS-CoV infections, particularly due to the rapid mutation of the spike protein that facilitates viral transmission across species from animals to humans.
Innovation Solution
Development of synthetic peptides that target specific regions of the SARS-CoV spike protein, including peptides represented by SEQ ID NOs.:2, 6, 8, and 10, which interfere with the protein's function to inhibit viral infection, and a method using real-time quantitative PCR to test antiviral activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional vaccines and antiviral drugs are used, then existing treatment options are available, but they are inadequate to effectively prevent and treat SARS-CoV infections due to rapid mutation of the spike protein
Solution Approach 1:
The invention divides the spike protein into multiple variable regions (P1-P10) based on sequence variations between animal and human SARS-CoV. Synthetic peptides are designed to target each specific region individually, allowing the treatment to address multiple mutation sites simultaneously rather than relying on a single conventional antiviral mechanism that can be easily mutated.
Solution Approach 2:
The invention changes the molecular parameters of the antiviral agents by designing custom synthetic peptides with specific amino acid sequences that match the variable regions of the spike protein. These peptides are designed to bind competitively to the variable regions, disrupting the protein's function and preventing viral entry, thereby adapting to the rapid mutation rate of the virus.
2Reliability
If synthetic peptides targeting variable regions are designed, then antiviral activity can be achieved, but the complexity of identifying and targeting critical sites increases
Solution Approach 1:
The invention uses synthetic peptides that copy the amino acid sequences of critical variable regions from the spike protein. By creating peptide versions of these regions (P1-P10), the peptides can bind competitively to the actual viral protein, blocking its function. This copying approach simplifies the targeting process by using molecular mimics rather than requiring complex structural analysis of the entire virus.
Solution Approach 2:
The invention extracts the critical variable regions from the full spike protein sequence and focuses the antiviral action on these specific segments. By identifying and isolating the most important variable regions (P1-P10) that differ between animal and human viruses, the invention can design peptides that specifically target these critical sites, reducing the complexity of dealing with the entire complex spike protein structure.
3Reliability
If multiple peptides are used in combination, then synergistic antiviral effects are achieved, but the complexity of testing and optimizing combinations increases
Solution Approach 1:
The invention segments the antiviral strategy into multiple independent peptide components (P1-P10), each targeting a specific variable region. This segmentation allows for systematic testing of individual peptides and their combinations, making it easier to identify synergistic effects. Rather than testing a single complex formulation, the segmented approach enables modular combination testing to optimize antiviral activity.
Data Source
AI summary
The present invention provides methods for locating critical portions or sites on the spike protein (S protein) of SARS-associated coronavirus (SARS-CoV) responsible for the viral infection that causes Severe Acute Respiratory Syndrome (SARS). The present invention also provides new synthetic peptides targeting such critical portions or sites of the S protein of SARS-CoV for preventing or treating of SARS-CoV infection in a subject. The present invention further provides methods of testing antiviral activity exerted by antiviral agents using real-time quantitative PCR.